Here’s what you should know:
1. Zacks analysts believe Allergan is actively reworking its portfolio through strategic acquisitions.
2. Zacks believes Allergan’s sale of Anda last year, has marked the drug maker as a “branded biopharmaceutical leader.” Allergan can build around its branded segments and use proceeds to buy back shares, pay down debt and further push its acquisitions in those areas.
3. Allergan’s Botox, Linzess, Viberzi and Vraylar all have strong public demand resulting in equally strong sales.
4. Zacks is “optimistic” about the company’s future, but worried by upcoming patent challenges to several of Allergan’s products. Zacks expects a generic of Namenda XR, to treat the symptoms of moderate-to-severe Alzheimer’s disease, could launch in 2017.
More articles on gastroenterology:
GI leader to know: Dr. Michael Thiim of Massachusetts General Hospital
GI center to know: Gastroenterology Associates
5 stats on GI net revenue per case at multispecialty ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.